Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Colorectal Neoplasms 3Sarcoma 2Carcinoma, Renal Cell 2Prostatic Neoplasms 1Lymphatic Metastasis 1Ependymoma 1Colonic Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Bone Neoplasms 1

Interventions

pembrolizumab 69Nivolumab 67cabozantinib 45Ipilimumab 36Specimen Handling 32Magnetic Resonance Spectroscopy 32lenvatinib 26Axitinib 25belzutifan 21Sunitinib 17Biopsy 15Radiosurgery 14CTLA-4 Antigen 13atezolizumab 12Everolimus 10pazopanib 8fludarabine 8avelumab 8Bevacizumab 8toripalimab 7cemiplimab 7Nephrectomy 7Immunoglobulin G 7Cyclophosphamide 7aldesleukin 6Standard of Care 6Radiotherapy 6Blood Specimen Collection 6spartalizumab 5palbociclib 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma, Renal Cell × Metastasectomy × 1 year × Clear all
NCT02210117 2026-06-01

Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
104 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

University of California, San Francisco

Phase 2 Terminated
6 enrolled 11 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡